News

KIT Mutation Testing Yields Survival Benefit for GIST Patients

09/03/2020

A long-term analysis of patients with localized and metastatic GIST determined there were survival differences associated with KIT mutation testing and other clinical variables.

A long-term analysis of patients...

09/03/2020

Oncology

News

Avapritinib Active Against Unresectable PDGFRA D842V-Mutant GIST

07/17/2020

Avapritinib had a manageable safety profile and demonstrated activity in patients with PDGFRA D842V-mutant GIST in the NAVIGATOR trial.

Avapritinib had a manageable...

07/17/2020

Oncology

News

Extended Imatinib Therapy Post-Resection Improves Survival in High-Risk GIST

06/09/2020

After a median follow-up of 10 years, 3 years of adjuvant imatinib was associated with significantly improved RFS and OS compared with 1 year of imatinib, after surgery, in patients with high risk-GIST.

After a median follow-up of 10...

06/09/2020

Oncology

News

FDA Approves Ripretinib for Pretreated Adults With Advanced GIST

05/15/2020

The FDA has approved ripretinib for the treatment of adults with advanced GIST who have received therapy with ≥3 or more kinase inhibitors, including imatinib.

The FDA has approved ripretinib...

05/15/2020

Oncology

News

OS More Affected by Tumor Rupture Than Surgery Type in GIST

04/07/2020

OS in patients with GIST is impacted more by tumor rupture than quality of surgery or treatment with adjuvant imatinib, a substudy has shown.

OS in patients with GIST is...

04/07/2020

Oncology

News

Better Survival With Complete Resection, Presurgery Imatinib for Giant GIST

03/16/2020

Presurgery imatinib or R0 resection were the best treatment options for patients with giant GIST in a retrospective study.

Presurgery imatinib or R0...

03/16/2020

Oncology

News

NGS of Plasma ctDNA Valuable for Detecting KIT Mutations in Metastatic GIST

02/10/2020

Plasma NGS was found to be valuable for detecting KIT primary and secondary mutations in patients with metastatic GIST, study findings show.

Plasma NGS was found to be...

02/10/2020

Oncology

News

Therapeutic Monitoring of Sunitinib Shows Potential in Adults With GIST and Metastatic RCC

01/24/2020

Review findings support the use of sunitinib dose modification guided by therapeutic drug monitoring in certain patients with RCC and GIST.

Review findings support the use...

01/24/2020

Oncology

News

FDA Approves Avapritinib as First Targeted Therapy for Rare GIST Mutation

01/09/2020

The FDA has approved avapritinib for the treatment of adults with unresectable or metastatic GIST harboring a PDGFRA exon 18 mutation.

The FDA has approved avapritinib...

01/09/2020

Oncology

News

5-Year Adjuvant Imatinib Yields Positive Outcomes, Low Adherence Rates in Patients With Primary GIST

12/20/2018

Extended duration of adjuvant therapy with imatinib shows efficacy in certain patients with gastrointestinal stromal tumors, but adherence to therapy remains a challenge.

Extended duration of adjuvant...

12/20/2018

Oncology

Recent News

News

Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer

11/14/2024

Allison Casey ;

According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.

According to a retrospective...

11/14/2024

Oncology

News

Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer

11/14/2024

Stephanie Holland ;

According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.

According to results from the...

11/14/2024

Oncology

News

Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma

11/13/2024

Stephanie Holland ;

Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.

Results from the phase 2...

11/13/2024

Oncology

News

Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

11/12/2024

Allison Casey ;

According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...

According to a phase 2b trial,...

11/12/2024

Oncology

News

Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer

11/12/2024

Stephanie Holland ;

According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.

According to final results from...

11/12/2024

Oncology

News

Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer

11/11/2024

Allison Casey ;

According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.

According to results from a...

11/11/2024

Oncology

FDA Approval

FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

11/08/2024

On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

On November 8, 2024, the FDA...

11/08/2024

Oncology

News

Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer

11/07/2024

Allison Casey ;

While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.

While naporafenib plus...

11/07/2024

Oncology

News

Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer

11/06/2024

Stephanie Holland ;

According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.

According to results from a...

11/06/2024

Oncology

News

Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma

11/05/2024

Allison Casey ;

A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.

A single-center real-world study...

11/05/2024

Oncology